EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta‐analysis of randomized placebo‐controlled trials

Houli Luo, Jian Feng, Yanbiao Zhang, Jie Wang, Gang Xue, Xi Huang, Shuang You, Hongfei Dong, Lingfan Li, Juncheng Li, Hualin Xiao, Xiang Ai und 2 weitere

Therapeutic Apheresis and Dialysis · 2023

DOI: 10.1111/1744-9987.14028 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Therapeutic Apheresis and Dialysis, 2023. Verfasst von Houli Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Cheng du First People's Hospital, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Hyperphosphatemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: The General Hospital of Western Theater Command, The Military Medical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effects of tenapanor in reducing serum phosphorus in hemodialysis patients with hyperphosphatemia are uncertain and no relevant meta‐analysis has been conducted. We performed a meta‐analysis of randomized placebo‐controlled trials to evaluate the efficacy and safety of tenapanor.

Methods

All randomized controlled trials of tenapanor were searched up to 1 August 2022. The primary endpoint was the change in serum phosphorus level from baseline with tenapanor and placebo. Data on drug‐related adverse events (AEs), gastrointestinal AEs and diarrhea were collected to determine the safety of tenapanor.

Results

There were 533 patients throughout five trials that were eligible. Tenapanor significantly lowered blood phosphorus level by 1.79 mg/dl in the mean difference than the placebo. Diarrhea, gastrointestinal AEs, and drug‐related AEs were more severe than placebo.

Conclusions

This meta‐analysis showed that although drug side effects were common, tenapanor significantly reduced serum phosphorus level in hemodialysis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaHumansDouble-Blind MethodRenal DialysisDiarrheaPhosphorusRandomized Controlled Trials as TopicIsoquinolinesSulfonamides

Stichwörter der Autor:innen

Tenapanorchronic kidney diseasehemodialysishyperphosphatemiameta-analysisplacebo-controlled trials

Substanzen

PhosphorustenapanorIsoquinolinesSulfonamides

Autor:innen und Institutionen

  • Department of Radiology, Cheng du First People's Hospital, Chengdu, Sichuan, China.
  • Department of Critical Care Medicine, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
  • Department of Burn and Plastic, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.

ORCID-Profile: Bo Huang

Förderung

  • The General Hospital of Western Theater Command, The Military Medical Research Program

Zitieren

APA

Luo, H., Feng, J., Zhang, Y., Wang, J., Xue, G., Huang, X., You, S., Dong, H., Li, L., Li, J., Xiao, H., Ai, X., Li, X., & Huang, B. (2023). Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14028

Vancouver

Luo H, Feng J, Zhang Y, Wang J, Xue G, Huang X, et al. Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Therapeutic Apheresis and Dialysis. 2023. doi:10.1111/1744-9987.14028

BibTeX
@article{Luo2023,
  author = {Luo, Houli and Feng, Jian and Zhang, Yanbiao and Wang, Jie and Xue, Gang and Huang, Xi and You, Shuang and Dong, Hongfei and Li, Lingfan and Li, Juncheng and Xiao, Hualin and Ai, Xiang and Li, Xianhui and Huang, Bo},
  title = {Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta‐analysis of randomized placebo‐controlled trials},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2023},
  doi = {10.1111/1744-9987.14028}
}
Kostenlos starten →